- Home
- MVIS vs CGEN Comparison
MVIS vs CGEN Comparison
Compare MVIS & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVIS | CGEN |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.6M | 191.1M |
| IPO Year | 2010 | 2001 |
Fundamental Metrics
Financial Performance| Metric | MVIS | CGEN |
|---|---|---|
| Price | $0.29 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.25 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 8.9M | 411.7K |
| Earning Date | 05-12-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $664,000.00 | N/A |
| Revenue This Year | $529.06 | N/A |
| Revenue Next Year | $168.46 | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $1.30 |
| 52 Week High | $1.73 | $3.24 |
Technical Indicators
Market Signals| Indicator | MVIS | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 23.31 | 40.66 |
| Support Level | N/A | $1.98 |
| Resistance Level | $0.73 | $2.35 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 1.36 | 65.82 |
Price Performance
Historical ComparisonAbout MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.